At the current stage of trials that ($100 share price) is quite a stretch, but within a year or two after testing our products in all the high, high revenue streams they could target, that is the lower end of the spectrum from what I have gathered from people I respect.
Dermatology - Eczema, acne, and other egregious conditions
Auto-Immune - There are about 100 of them
IBD - Entire GI tract
Cancer - Combinatory drug with most other cancer treatments?
p53 modulation also seems to have many other
non-cancer areas not yet researched
Anti-biotic - Only new class of antibiotic in decades and only one
that appears to prevent resistance to it. Uses
include wounds,eye,ear,etc infections
Industrial polymer B - Paints, plastics, textiles, tools, etc
These are just the revenue streams that have already been identified to date and I believe Dr B said that they haven't even scratched the surface of possible B applications yet. Add up the revenues of the above revenue streams and I think you come up with dang near a couple hundred billion dollars per year, so yeah, $100 not a pipe dream.
Now I am not saying IPIX needs to do all the above legwork, they just have to have partnership deals where we get significant royalties on ALL INDICATIONS relating to our 3 products thru the life of such medications. That way BP is making a killing, we make a killing, and patients reap the rewards of far better lives.
News 
Market Data 
Discover 
AI
